News
News from us and our partners
News
News
Biovelocita
News
Crossover
News
News
Industrial Biotech
News
Capital
News
Digital Medicine
News
Sofinnova Partners raises €1.2 billion to fuel the next wave of life sciences innovation
Sofinnova Partners exceeds target with €165M biotech acceleration fund, Europe’s largest, with strong Pharma support
CEO spotlight: Thierry Abribat's third straight win
Sofinnova’s newest partners discuss their career paths
Sofinnova publishes 2023 Impact Report
Johnson & Johnson to acquire Shockwave Medical
Cure51 raises €15 million to harness the power of cancer survivors
CEO spotlight: CinCor's Marc de Garidel
Tags
Topics
0 results
- News
Verley becomes first company to receive FDA "No Questions Letter" for functionalized dairy Proteins made via precision fermentation
- News
NanoPhoria Bioscience secures €83.5 Million Series A to advance breakthrough heart failure therapy and expand portfolio for novel Nano-in-Micro delivery platform
- News
AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease
- News
Sitryx receives FDA clearance of IND application for SYX-5219 for the treatment of atopic dermatitis
- News
Inventiva Appoints Andrew Obenshain as Chief Executive Officer
- News
ADC Innovator Myricx Bio Appoints Boston-based Mohit Rawat as CEO and Expands Team in US and UK
- News
Myricx Bio Further Strengthens its Clinical Team and US Presence with the Appointment of David Ellis as VP, Regulatory Affairs
- News
Bioptimus Assembles Elite Scientific Advisory Board to Build Next-Gen AI Models for Biology
- News
Arzeda to Lead Major NSF-Funded Initiative Advancing Cell-Free Manufacturing Through AI-Designed Enzymes
- News
Sitryx appoints Adam Mostafa as Chief Financial Officer
- News
TISSIUM Advances Clinical Pipeline in Hernia Repair Following First FDA Authorization
- News
Galvanize Therapeutics raises $100 million in oversubscribed Series C financing to transform the treatment of cancer and chronic lung disease
- News
BrightHeart Sets New Standard in Prenatal CHD Screening with Landmark Study Published in Obstetrics & Gynecology
- News
Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial
- News
AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease